Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): consultee and commentator comments on the ACD

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Roche
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): British Thoracic Society
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Royal College of Pathologists
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Department of Health
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NHS Derby City
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Commissioning Support Appraisals Service
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): AstraZeneca UK
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): Lilly

This page was last updated: 08 May 2012